From: Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study
ANA after IFX
EULAR
Increased
No change
P value a
response
(n = 13)
(n = 76)
Good
8%
54%
0.001
(Remission)
(0)
(42%)
Moderate
15%
20%
No
77%
26%